nodes	percent_of_prediction	percent_of_DWPC	metapath
Ganciclovir—Nucleoside Analog—Azathioprine—systemic scleroderma	0.723	1	CiPCiCtD
Ganciclovir—SLC22A6—Captopril—systemic scleroderma	0.0539	0.398	CbGbCtD
Ganciclovir—SLC22A7—Methotrexate—systemic scleroderma	0.04	0.296	CbGbCtD
Ganciclovir—SLC22A8—Methotrexate—systemic scleroderma	0.0244	0.18	CbGbCtD
Ganciclovir—SLC22A6—Methotrexate—systemic scleroderma	0.017	0.126	CbGbCtD
Ganciclovir—Pain—Mycophenolic acid—systemic scleroderma	6.3e-05	0.000446	CcSEcCtD
Ganciclovir—Weight decreased—Prednisone—systemic scleroderma	6.27e-05	0.000444	CcSEcCtD
Ganciclovir—Hyperglycaemia—Prednisone—systemic scleroderma	6.25e-05	0.000443	CcSEcCtD
Ganciclovir—Cough—Mycophenolate mofetil—systemic scleroderma	6.22e-05	0.00044	CcSEcCtD
Ganciclovir—Hypotension—Lisinopril—systemic scleroderma	6.2e-05	0.000439	CcSEcCtD
Ganciclovir—Dizziness—Captopril—systemic scleroderma	6.2e-05	0.000439	CcSEcCtD
Ganciclovir—Liver function test abnormal—Methotrexate—systemic scleroderma	6.19e-05	0.000438	CcSEcCtD
Ganciclovir—Convulsion—Mycophenolate mofetil—systemic scleroderma	6.17e-05	0.000437	CcSEcCtD
Ganciclovir—Hypertension—Mycophenolate mofetil—systemic scleroderma	6.15e-05	0.000436	CcSEcCtD
Ganciclovir—Urticaria—Leflunomide—systemic scleroderma	6.14e-05	0.000435	CcSEcCtD
Ganciclovir—Body temperature increased—Leflunomide—systemic scleroderma	6.11e-05	0.000433	CcSEcCtD
Ganciclovir—Abdominal pain—Leflunomide—systemic scleroderma	6.11e-05	0.000433	CcSEcCtD
Ganciclovir—Feeling abnormal—Mycophenolic acid—systemic scleroderma	6.07e-05	0.00043	CcSEcCtD
Ganciclovir—Myalgia—Mycophenolate mofetil—systemic scleroderma	6.07e-05	0.00043	CcSEcCtD
Ganciclovir—Chest pain—Mycophenolate mofetil—systemic scleroderma	6.07e-05	0.00043	CcSEcCtD
Ganciclovir—Arthralgia—Mycophenolate mofetil—systemic scleroderma	6.07e-05	0.00043	CcSEcCtD
Ganciclovir—Neuropathy peripheral—Prednisone—systemic scleroderma	6.06e-05	0.000429	CcSEcCtD
Ganciclovir—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	6.05e-05	0.000428	CcSEcCtD
Ganciclovir—Anxiety—Mycophenolate mofetil—systemic scleroderma	6.05e-05	0.000428	CcSEcCtD
Ganciclovir—Hypersensitivity—Azathioprine—systemic scleroderma	6.03e-05	0.000427	CcSEcCtD
Ganciclovir—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	6.03e-05	0.000427	CcSEcCtD
Ganciclovir—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	6.03e-05	0.000427	CcSEcCtD
Ganciclovir—Insomnia—Lisinopril—systemic scleroderma	6e-05	0.000425	CcSEcCtD
Ganciclovir—Discomfort—Mycophenolate mofetil—systemic scleroderma	5.99e-05	0.000425	CcSEcCtD
Ganciclovir—Paraesthesia—Lisinopril—systemic scleroderma	5.96e-05	0.000422	CcSEcCtD
Ganciclovir—Vomiting—Captopril—systemic scleroderma	5.96e-05	0.000422	CcSEcCtD
Ganciclovir—Dry mouth—Mycophenolate mofetil—systemic scleroderma	5.93e-05	0.00042	CcSEcCtD
Ganciclovir—Dyspnoea—Lisinopril—systemic scleroderma	5.92e-05	0.000419	CcSEcCtD
Ganciclovir—Rash—Captopril—systemic scleroderma	5.91e-05	0.000419	CcSEcCtD
Ganciclovir—Dermatitis—Captopril—systemic scleroderma	5.9e-05	0.000418	CcSEcCtD
Ganciclovir—Somnolence—Lisinopril—systemic scleroderma	5.9e-05	0.000418	CcSEcCtD
Ganciclovir—Headache—Captopril—systemic scleroderma	5.87e-05	0.000416	CcSEcCtD
Ganciclovir—Confusional state—Mycophenolate mofetil—systemic scleroderma	5.86e-05	0.000415	CcSEcCtD
Ganciclovir—Dyspepsia—Lisinopril—systemic scleroderma	5.84e-05	0.000414	CcSEcCtD
Ganciclovir—Abdominal pain—Mycophenolic acid—systemic scleroderma	5.83e-05	0.000413	CcSEcCtD
Ganciclovir—Body temperature increased—Mycophenolic acid—systemic scleroderma	5.83e-05	0.000413	CcSEcCtD
Ganciclovir—Oedema—Mycophenolate mofetil—systemic scleroderma	5.82e-05	0.000412	CcSEcCtD
Ganciclovir—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	5.82e-05	0.000412	CcSEcCtD
Ganciclovir—Infection—Mycophenolate mofetil—systemic scleroderma	5.78e-05	0.000409	CcSEcCtD
Ganciclovir—Decreased appetite—Lisinopril—systemic scleroderma	5.77e-05	0.000409	CcSEcCtD
Ganciclovir—Eosinophilia—Methotrexate—systemic scleroderma	5.74e-05	0.000406	CcSEcCtD
Ganciclovir—Gastrointestinal disorder—Lisinopril—systemic scleroderma	5.73e-05	0.000406	CcSEcCtD
Ganciclovir—Fatigue—Lisinopril—systemic scleroderma	5.72e-05	0.000405	CcSEcCtD
Ganciclovir—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	5.69e-05	0.000403	CcSEcCtD
Ganciclovir—Hypersensitivity—Leflunomide—systemic scleroderma	5.69e-05	0.000403	CcSEcCtD
Ganciclovir—Pancreatitis—Methotrexate—systemic scleroderma	5.68e-05	0.000402	CcSEcCtD
Ganciclovir—Pain—Lisinopril—systemic scleroderma	5.68e-05	0.000402	CcSEcCtD
Ganciclovir—Constipation—Lisinopril—systemic scleroderma	5.68e-05	0.000402	CcSEcCtD
Ganciclovir—Tachycardia—Mycophenolate mofetil—systemic scleroderma	5.68e-05	0.000402	CcSEcCtD
Ganciclovir—Skin disorder—Mycophenolate mofetil—systemic scleroderma	5.65e-05	0.0004	CcSEcCtD
Ganciclovir—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	5.62e-05	0.000398	CcSEcCtD
Ganciclovir—Diarrhoea—Azathioprine—systemic scleroderma	5.6e-05	0.000396	CcSEcCtD
Ganciclovir—Haemoglobin—Prednisone—systemic scleroderma	5.58e-05	0.000395	CcSEcCtD
Ganciclovir—Nausea—Captopril—systemic scleroderma	5.57e-05	0.000394	CcSEcCtD
Ganciclovir—Haemorrhage—Prednisone—systemic scleroderma	5.55e-05	0.000393	CcSEcCtD
Ganciclovir—Anorexia—Mycophenolate mofetil—systemic scleroderma	5.54e-05	0.000393	CcSEcCtD
Ganciclovir—Asthenia—Leflunomide—systemic scleroderma	5.54e-05	0.000393	CcSEcCtD
Ganciclovir—Hallucination—Prednisone—systemic scleroderma	5.52e-05	0.000391	CcSEcCtD
Ganciclovir—Pancytopenia—Methotrexate—systemic scleroderma	5.5e-05	0.00039	CcSEcCtD
Ganciclovir—Feeling abnormal—Lisinopril—systemic scleroderma	5.47e-05	0.000387	CcSEcCtD
Ganciclovir—Pruritus—Leflunomide—systemic scleroderma	5.47e-05	0.000387	CcSEcCtD
Ganciclovir—Connective tissue disorder—Prednisone—systemic scleroderma	5.45e-05	0.000386	CcSEcCtD
Ganciclovir—Hypotension—Mycophenolate mofetil—systemic scleroderma	5.43e-05	0.000385	CcSEcCtD
Ganciclovir—Gastrointestinal pain—Lisinopril—systemic scleroderma	5.43e-05	0.000384	CcSEcCtD
Ganciclovir—Dysuria—Methotrexate—systemic scleroderma	5.42e-05	0.000384	CcSEcCtD
Ganciclovir—Neutropenia—Methotrexate—systemic scleroderma	5.42e-05	0.000384	CcSEcCtD
Ganciclovir—Dizziness—Azathioprine—systemic scleroderma	5.41e-05	0.000383	CcSEcCtD
Ganciclovir—Upper respiratory tract infection—Methotrexate—systemic scleroderma	5.38e-05	0.000381	CcSEcCtD
Ganciclovir—Erectile dysfunction—Methotrexate—systemic scleroderma	5.34e-05	0.000378	CcSEcCtD
Ganciclovir—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	5.3e-05	0.000375	CcSEcCtD
Ganciclovir—Photosensitivity reaction—Methotrexate—systemic scleroderma	5.29e-05	0.000375	CcSEcCtD
Ganciclovir—Asthenia—Mycophenolic acid—systemic scleroderma	5.29e-05	0.000375	CcSEcCtD
Ganciclovir—Diarrhoea—Leflunomide—systemic scleroderma	5.29e-05	0.000374	CcSEcCtD
Ganciclovir—Urticaria—Lisinopril—systemic scleroderma	5.27e-05	0.000374	CcSEcCtD
Ganciclovir—Insomnia—Mycophenolate mofetil—systemic scleroderma	5.26e-05	0.000373	CcSEcCtD
Ganciclovir—Abdominal pain—Lisinopril—systemic scleroderma	5.25e-05	0.000372	CcSEcCtD
Ganciclovir—Body temperature increased—Lisinopril—systemic scleroderma	5.25e-05	0.000372	CcSEcCtD
Ganciclovir—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	5.22e-05	0.00037	CcSEcCtD
Ganciclovir—Pruritus—Mycophenolic acid—systemic scleroderma	5.21e-05	0.000369	CcSEcCtD
Ganciclovir—Vomiting—Azathioprine—systemic scleroderma	5.2e-05	0.000368	CcSEcCtD
Ganciclovir—Pneumonia—Methotrexate—systemic scleroderma	5.2e-05	0.000368	CcSEcCtD
Ganciclovir—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	5.19e-05	0.000367	CcSEcCtD
Ganciclovir—Somnolence—Mycophenolate mofetil—systemic scleroderma	5.17e-05	0.000366	CcSEcCtD
Ganciclovir—Infestation NOS—Methotrexate—systemic scleroderma	5.17e-05	0.000366	CcSEcCtD
Ganciclovir—Infestation—Methotrexate—systemic scleroderma	5.17e-05	0.000366	CcSEcCtD
Ganciclovir—Rash—Azathioprine—systemic scleroderma	5.16e-05	0.000365	CcSEcCtD
Ganciclovir—Dermatitis—Azathioprine—systemic scleroderma	5.15e-05	0.000365	CcSEcCtD
Ganciclovir—Headache—Azathioprine—systemic scleroderma	5.12e-05	0.000363	CcSEcCtD
Ganciclovir—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	5.12e-05	0.000363	CcSEcCtD
Ganciclovir—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	5.12e-05	0.000363	CcSEcCtD
Ganciclovir—Dizziness—Leflunomide—systemic scleroderma	5.11e-05	0.000362	CcSEcCtD
Ganciclovir—Renal failure—Methotrexate—systemic scleroderma	5.08e-05	0.00036	CcSEcCtD
Ganciclovir—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	5.06e-05	0.000358	CcSEcCtD
Ganciclovir—Diarrhoea—Mycophenolic acid—systemic scleroderma	5.04e-05	0.000357	CcSEcCtD
Ganciclovir—Stomatitis—Methotrexate—systemic scleroderma	5.04e-05	0.000357	CcSEcCtD
Ganciclovir—Angiopathy—Prednisone—systemic scleroderma	5.03e-05	0.000357	CcSEcCtD
Ganciclovir—Conjunctivitis—Methotrexate—systemic scleroderma	5.02e-05	0.000356	CcSEcCtD
Ganciclovir—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	5.02e-05	0.000356	CcSEcCtD
Ganciclovir—Pain—Mycophenolate mofetil—systemic scleroderma	4.97e-05	0.000352	CcSEcCtD
Ganciclovir—Constipation—Mycophenolate mofetil—systemic scleroderma	4.97e-05	0.000352	CcSEcCtD
Ganciclovir—Arrhythmia—Prednisone—systemic scleroderma	4.96e-05	0.000351	CcSEcCtD
Ganciclovir—Sweating—Methotrexate—systemic scleroderma	4.95e-05	0.000351	CcSEcCtD
Ganciclovir—Haematuria—Methotrexate—systemic scleroderma	4.93e-05	0.000349	CcSEcCtD
Ganciclovir—Vomiting—Leflunomide—systemic scleroderma	4.91e-05	0.000348	CcSEcCtD
Ganciclovir—Alopecia—Prednisone—systemic scleroderma	4.9e-05	0.000347	CcSEcCtD
Ganciclovir—Hypersensitivity—Lisinopril—systemic scleroderma	4.89e-05	0.000346	CcSEcCtD
Ganciclovir—Hepatobiliary disease—Methotrexate—systemic scleroderma	4.89e-05	0.000346	CcSEcCtD
Ganciclovir—Dizziness—Mycophenolic acid—systemic scleroderma	4.87e-05	0.000345	CcSEcCtD
Ganciclovir—Rash—Leflunomide—systemic scleroderma	4.87e-05	0.000345	CcSEcCtD
Ganciclovir—Dermatitis—Leflunomide—systemic scleroderma	4.87e-05	0.000345	CcSEcCtD
Ganciclovir—Mental disorder—Prednisone—systemic scleroderma	4.86e-05	0.000344	CcSEcCtD
Ganciclovir—Nausea—Azathioprine—systemic scleroderma	4.86e-05	0.000344	CcSEcCtD
Ganciclovir—Headache—Leflunomide—systemic scleroderma	4.84e-05	0.000343	CcSEcCtD
Ganciclovir—Malnutrition—Prednisone—systemic scleroderma	4.83e-05	0.000342	CcSEcCtD
Ganciclovir—Agranulocytosis—Methotrexate—systemic scleroderma	4.82e-05	0.000341	CcSEcCtD
Ganciclovir—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	4.79e-05	0.000339	CcSEcCtD
Ganciclovir—Asthenia—Lisinopril—systemic scleroderma	4.76e-05	0.000337	CcSEcCtD
Ganciclovir—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	4.76e-05	0.000337	CcSEcCtD
Ganciclovir—Pruritus—Lisinopril—systemic scleroderma	4.7e-05	0.000333	CcSEcCtD
Ganciclovir—Vomiting—Mycophenolic acid—systemic scleroderma	4.69e-05	0.000332	CcSEcCtD
Ganciclovir—Haemoglobin—Methotrexate—systemic scleroderma	4.66e-05	0.00033	CcSEcCtD
Ganciclovir—Rash—Mycophenolic acid—systemic scleroderma	4.65e-05	0.000329	CcSEcCtD
Ganciclovir—Dermatitis—Mycophenolic acid—systemic scleroderma	4.64e-05	0.000329	CcSEcCtD
Ganciclovir—Haemorrhage—Methotrexate—systemic scleroderma	4.64e-05	0.000329	CcSEcCtD
Ganciclovir—Hepatitis—Methotrexate—systemic scleroderma	4.64e-05	0.000329	CcSEcCtD
Ganciclovir—Urticaria—Mycophenolate mofetil—systemic scleroderma	4.62e-05	0.000327	CcSEcCtD
Ganciclovir—Headache—Mycophenolic acid—systemic scleroderma	4.62e-05	0.000327	CcSEcCtD
Ganciclovir—Pharyngitis—Methotrexate—systemic scleroderma	4.6e-05	0.000326	CcSEcCtD
Ganciclovir—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	4.6e-05	0.000326	CcSEcCtD
Ganciclovir—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	4.6e-05	0.000326	CcSEcCtD
Ganciclovir—Nausea—Leflunomide—systemic scleroderma	4.59e-05	0.000325	CcSEcCtD
Ganciclovir—Urinary tract disorder—Methotrexate—systemic scleroderma	4.58e-05	0.000324	CcSEcCtD
Ganciclovir—Vision blurred—Prednisone—systemic scleroderma	4.55e-05	0.000322	CcSEcCtD
Ganciclovir—Urethral disorder—Methotrexate—systemic scleroderma	4.55e-05	0.000322	CcSEcCtD
Ganciclovir—Diarrhoea—Lisinopril—systemic scleroderma	4.54e-05	0.000322	CcSEcCtD
Ganciclovir—Ill-defined disorder—Prednisone—systemic scleroderma	4.48e-05	0.000317	CcSEcCtD
Ganciclovir—Visual impairment—Methotrexate—systemic scleroderma	4.47e-05	0.000317	CcSEcCtD
Ganciclovir—Anaemia—Prednisone—systemic scleroderma	4.46e-05	0.000316	CcSEcCtD
Ganciclovir—Agitation—Prednisone—systemic scleroderma	4.44e-05	0.000314	CcSEcCtD
Ganciclovir—Dizziness—Lisinopril—systemic scleroderma	4.39e-05	0.000311	CcSEcCtD
Ganciclovir—Erythema multiforme—Methotrexate—systemic scleroderma	4.38e-05	0.000311	CcSEcCtD
Ganciclovir—Nausea—Mycophenolic acid—systemic scleroderma	4.38e-05	0.00031	CcSEcCtD
Ganciclovir—Malaise—Prednisone—systemic scleroderma	4.36e-05	0.000309	CcSEcCtD
Ganciclovir—Vertigo—Prednisone—systemic scleroderma	4.34e-05	0.000307	CcSEcCtD
Ganciclovir—Tinnitus—Methotrexate—systemic scleroderma	4.32e-05	0.000306	CcSEcCtD
Ganciclovir—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	4.29e-05	0.000304	CcSEcCtD
Ganciclovir—Vomiting—Lisinopril—systemic scleroderma	4.22e-05	0.000299	CcSEcCtD
Ganciclovir—Angiopathy—Methotrexate—systemic scleroderma	4.21e-05	0.000298	CcSEcCtD
Ganciclovir—Rash—Lisinopril—systemic scleroderma	4.19e-05	0.000296	CcSEcCtD
Ganciclovir—Convulsion—Prednisone—systemic scleroderma	4.19e-05	0.000296	CcSEcCtD
Ganciclovir—Dermatitis—Lisinopril—systemic scleroderma	4.18e-05	0.000296	CcSEcCtD
Ganciclovir—Mediastinal disorder—Methotrexate—systemic scleroderma	4.18e-05	0.000296	CcSEcCtD
Ganciclovir—Asthenia—Mycophenolate mofetil—systemic scleroderma	4.17e-05	0.000296	CcSEcCtD
Ganciclovir—Hypertension—Prednisone—systemic scleroderma	4.17e-05	0.000295	CcSEcCtD
Ganciclovir—Chills—Methotrexate—systemic scleroderma	4.16e-05	0.000295	CcSEcCtD
Ganciclovir—Headache—Lisinopril—systemic scleroderma	4.16e-05	0.000295	CcSEcCtD
Ganciclovir—Pruritus—Mycophenolate mofetil—systemic scleroderma	4.11e-05	0.000291	CcSEcCtD
Ganciclovir—Myalgia—Prednisone—systemic scleroderma	4.11e-05	0.000291	CcSEcCtD
Ganciclovir—Arthralgia—Prednisone—systemic scleroderma	4.11e-05	0.000291	CcSEcCtD
Ganciclovir—Anxiety—Prednisone—systemic scleroderma	4.1e-05	0.00029	CcSEcCtD
Ganciclovir—Alopecia—Methotrexate—systemic scleroderma	4.1e-05	0.00029	CcSEcCtD
Ganciclovir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	4.08e-05	0.000289	CcSEcCtD
Ganciclovir—Discomfort—Prednisone—systemic scleroderma	4.06e-05	0.000288	CcSEcCtD
Ganciclovir—Mental disorder—Methotrexate—systemic scleroderma	4.06e-05	0.000288	CcSEcCtD
Ganciclovir—Malnutrition—Methotrexate—systemic scleroderma	4.04e-05	0.000286	CcSEcCtD
Ganciclovir—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	3.98e-05	0.000282	CcSEcCtD
Ganciclovir—Dysgeusia—Methotrexate—systemic scleroderma	3.95e-05	0.00028	CcSEcCtD
Ganciclovir—Nausea—Lisinopril—systemic scleroderma	3.94e-05	0.000279	CcSEcCtD
Ganciclovir—Anaphylactic shock—Prednisone—systemic scleroderma	3.94e-05	0.000279	CcSEcCtD
Ganciclovir—Oedema—Prednisone—systemic scleroderma	3.94e-05	0.000279	CcSEcCtD
Ganciclovir—Infection—Prednisone—systemic scleroderma	3.92e-05	0.000277	CcSEcCtD
Ganciclovir—Back pain—Methotrexate—systemic scleroderma	3.91e-05	0.000277	CcSEcCtD
Ganciclovir—Tachycardia—Prednisone—systemic scleroderma	3.85e-05	0.000273	CcSEcCtD
Ganciclovir—Dizziness—Mycophenolate mofetil—systemic scleroderma	3.85e-05	0.000272	CcSEcCtD
Ganciclovir—Skin disorder—Prednisone—systemic scleroderma	3.83e-05	0.000271	CcSEcCtD
Ganciclovir—Hyperhidrosis—Prednisone—systemic scleroderma	3.81e-05	0.00027	CcSEcCtD
Ganciclovir—Vision blurred—Methotrexate—systemic scleroderma	3.8e-05	0.00027	CcSEcCtD
Ganciclovir—Anorexia—Prednisone—systemic scleroderma	3.76e-05	0.000266	CcSEcCtD
Ganciclovir—Ill-defined disorder—Methotrexate—systemic scleroderma	3.75e-05	0.000265	CcSEcCtD
Ganciclovir—Anaemia—Methotrexate—systemic scleroderma	3.73e-05	0.000264	CcSEcCtD
Ganciclovir—Vomiting—Mycophenolate mofetil—systemic scleroderma	3.7e-05	0.000262	CcSEcCtD
Ganciclovir—Rash—Mycophenolate mofetil—systemic scleroderma	3.67e-05	0.00026	CcSEcCtD
Ganciclovir—Dermatitis—Mycophenolate mofetil—systemic scleroderma	3.66e-05	0.00026	CcSEcCtD
Ganciclovir—Headache—Mycophenolate mofetil—systemic scleroderma	3.64e-05	0.000258	CcSEcCtD
Ganciclovir—Malaise—Methotrexate—systemic scleroderma	3.64e-05	0.000258	CcSEcCtD
Ganciclovir—Vertigo—Methotrexate—systemic scleroderma	3.63e-05	0.000257	CcSEcCtD
Ganciclovir—Leukopenia—Methotrexate—systemic scleroderma	3.61e-05	0.000256	CcSEcCtD
Ganciclovir—Musculoskeletal discomfort—Prednisone—systemic scleroderma	3.59e-05	0.000254	CcSEcCtD
Ganciclovir—Insomnia—Prednisone—systemic scleroderma	3.57e-05	0.000253	CcSEcCtD
Ganciclovir—Paraesthesia—Prednisone—systemic scleroderma	3.54e-05	0.000251	CcSEcCtD
Ganciclovir—Cough—Methotrexate—systemic scleroderma	3.52e-05	0.00025	CcSEcCtD
Ganciclovir—Convulsion—Methotrexate—systemic scleroderma	3.5e-05	0.000248	CcSEcCtD
Ganciclovir—Dyspepsia—Prednisone—systemic scleroderma	3.47e-05	0.000246	CcSEcCtD
Ganciclovir—Nausea—Mycophenolate mofetil—systemic scleroderma	3.45e-05	0.000245	CcSEcCtD
Ganciclovir—Myalgia—Methotrexate—systemic scleroderma	3.44e-05	0.000243	CcSEcCtD
Ganciclovir—Chest pain—Methotrexate—systemic scleroderma	3.44e-05	0.000243	CcSEcCtD
Ganciclovir—Arthralgia—Methotrexate—systemic scleroderma	3.44e-05	0.000243	CcSEcCtD
Ganciclovir—Decreased appetite—Prednisone—systemic scleroderma	3.43e-05	0.000243	CcSEcCtD
Ganciclovir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	3.41e-05	0.000242	CcSEcCtD
Ganciclovir—Fatigue—Prednisone—systemic scleroderma	3.4e-05	0.000241	CcSEcCtD
Ganciclovir—Discomfort—Methotrexate—systemic scleroderma	3.4e-05	0.000241	CcSEcCtD
Ganciclovir—Constipation—Prednisone—systemic scleroderma	3.37e-05	0.000239	CcSEcCtD
Ganciclovir—Confusional state—Methotrexate—systemic scleroderma	3.32e-05	0.000235	CcSEcCtD
Ganciclovir—Anaphylactic shock—Methotrexate—systemic scleroderma	3.29e-05	0.000233	CcSEcCtD
Ganciclovir—Infection—Methotrexate—systemic scleroderma	3.27e-05	0.000232	CcSEcCtD
Ganciclovir—Feeling abnormal—Prednisone—systemic scleroderma	3.25e-05	0.00023	CcSEcCtD
Ganciclovir—Thrombocytopenia—Methotrexate—systemic scleroderma	3.23e-05	0.000229	CcSEcCtD
Ganciclovir—Gastrointestinal pain—Prednisone—systemic scleroderma	3.22e-05	0.000228	CcSEcCtD
Ganciclovir—Skin disorder—Methotrexate—systemic scleroderma	3.2e-05	0.000227	CcSEcCtD
Ganciclovir—Hyperhidrosis—Methotrexate—systemic scleroderma	3.19e-05	0.000226	CcSEcCtD
Ganciclovir—Anorexia—Methotrexate—systemic scleroderma	3.14e-05	0.000222	CcSEcCtD
Ganciclovir—Urticaria—Prednisone—systemic scleroderma	3.13e-05	0.000222	CcSEcCtD
Ganciclovir—Body temperature increased—Prednisone—systemic scleroderma	3.12e-05	0.000221	CcSEcCtD
Ganciclovir—Abdominal pain—Prednisone—systemic scleroderma	3.12e-05	0.000221	CcSEcCtD
Ganciclovir—Hypotension—Methotrexate—systemic scleroderma	3.08e-05	0.000218	CcSEcCtD
Ganciclovir—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	3e-05	0.000213	CcSEcCtD
Ganciclovir—Insomnia—Methotrexate—systemic scleroderma	2.98e-05	0.000211	CcSEcCtD
Ganciclovir—Paraesthesia—Methotrexate—systemic scleroderma	2.96e-05	0.00021	CcSEcCtD
Ganciclovir—Dyspnoea—Methotrexate—systemic scleroderma	2.94e-05	0.000208	CcSEcCtD
Ganciclovir—Somnolence—Methotrexate—systemic scleroderma	2.93e-05	0.000207	CcSEcCtD
Ganciclovir—Hypersensitivity—Prednisone—systemic scleroderma	2.9e-05	0.000206	CcSEcCtD
Ganciclovir—Dyspepsia—Methotrexate—systemic scleroderma	2.9e-05	0.000205	CcSEcCtD
Ganciclovir—Decreased appetite—Methotrexate—systemic scleroderma	2.86e-05	0.000203	CcSEcCtD
Ganciclovir—Gastrointestinal disorder—Methotrexate—systemic scleroderma	2.84e-05	0.000201	CcSEcCtD
Ganciclovir—Fatigue—Methotrexate—systemic scleroderma	2.84e-05	0.000201	CcSEcCtD
Ganciclovir—Asthenia—Prednisone—systemic scleroderma	2.83e-05	0.0002	CcSEcCtD
Ganciclovir—Pain—Methotrexate—systemic scleroderma	2.82e-05	0.0002	CcSEcCtD
Ganciclovir—Pruritus—Prednisone—systemic scleroderma	2.79e-05	0.000198	CcSEcCtD
Ganciclovir—Feeling abnormal—Methotrexate—systemic scleroderma	2.72e-05	0.000192	CcSEcCtD
Ganciclovir—Diarrhoea—Prednisone—systemic scleroderma	2.7e-05	0.000191	CcSEcCtD
Ganciclovir—Gastrointestinal pain—Methotrexate—systemic scleroderma	2.69e-05	0.000191	CcSEcCtD
Ganciclovir—Urticaria—Methotrexate—systemic scleroderma	2.62e-05	0.000185	CcSEcCtD
Ganciclovir—Dizziness—Prednisone—systemic scleroderma	2.61e-05	0.000185	CcSEcCtD
Ganciclovir—Abdominal pain—Methotrexate—systemic scleroderma	2.6e-05	0.000184	CcSEcCtD
Ganciclovir—Body temperature increased—Methotrexate—systemic scleroderma	2.6e-05	0.000184	CcSEcCtD
Ganciclovir—Vomiting—Prednisone—systemic scleroderma	2.51e-05	0.000178	CcSEcCtD
Ganciclovir—Rash—Prednisone—systemic scleroderma	2.49e-05	0.000176	CcSEcCtD
Ganciclovir—Dermatitis—Prednisone—systemic scleroderma	2.48e-05	0.000176	CcSEcCtD
Ganciclovir—Headache—Prednisone—systemic scleroderma	2.47e-05	0.000175	CcSEcCtD
Ganciclovir—Hypersensitivity—Methotrexate—systemic scleroderma	2.43e-05	0.000172	CcSEcCtD
Ganciclovir—Asthenia—Methotrexate—systemic scleroderma	2.36e-05	0.000167	CcSEcCtD
Ganciclovir—Nausea—Prednisone—systemic scleroderma	2.34e-05	0.000166	CcSEcCtD
Ganciclovir—Pruritus—Methotrexate—systemic scleroderma	2.33e-05	0.000165	CcSEcCtD
Ganciclovir—Diarrhoea—Methotrexate—systemic scleroderma	2.25e-05	0.00016	CcSEcCtD
Ganciclovir—Dizziness—Methotrexate—systemic scleroderma	2.18e-05	0.000154	CcSEcCtD
Ganciclovir—Vomiting—Methotrexate—systemic scleroderma	2.09e-05	0.000148	CcSEcCtD
Ganciclovir—Rash—Methotrexate—systemic scleroderma	2.08e-05	0.000147	CcSEcCtD
Ganciclovir—Dermatitis—Methotrexate—systemic scleroderma	2.08e-05	0.000147	CcSEcCtD
Ganciclovir—Headache—Methotrexate—systemic scleroderma	2.06e-05	0.000146	CcSEcCtD
Ganciclovir—Nausea—Methotrexate—systemic scleroderma	1.96e-05	0.000139	CcSEcCtD
